Display options
Cite
Zhu Q, Ma Y, Liang J, et al. Correction: AHR mediates the Aflatoxin B1 toxicity associated with hepatocellular carcinoma. Signal Transduct Target Ther. 2021;6(1):432doi: 10.1038/s41392-021-00794-y.
Zhu, Q., Ma, Y., Liang, J., Wei, Z., Li, M., Zhang, Y., Liu, M., He, H., Qu, C., Cai, J., Wang, X., Zeng, Y., & Jiao, Y. (2021). Correction: AHR mediates the Aflatoxin B1 toxicity associated with hepatocellular carcinoma. Signal transduction and targeted therapy, 6(1), 432. https://doi.org/10.1038/s41392-021-00794-y
Zhu, Qing, et al. "Correction: AHR mediates the Aflatoxin B1 toxicity associated with hepatocellular carcinoma." Signal transduction and targeted therapy vol. 6,1 (2021): 432. doi: https://doi.org/10.1038/s41392-021-00794-y
Zhu Q, Ma Y, Liang J, Wei Z, Li M, Zhang Y, Liu M, He H, Qu C, Cai J, Wang X, Zeng Y, Jiao Y. Correction: AHR mediates the Aflatoxin B1 toxicity associated with hepatocellular carcinoma. Signal Transduct Target Ther. 2021 Dec 20;6(1):432. doi: 10.1038/s41392-021-00794-y. PMID: 34924560; PMCID: PMC8685275.
Copy Download .nbib Format: NLM
Share it on

Signal Transduct Target Ther. 2021 Dec 20;6(1):432. doi: 10.1038/s41392-021-00794-y.

Correction: AHR mediates the Aflatoxin B1 toxicity associated with hepatocellular carcinoma.

Signal transduction and targeted therapy

Qing Zhu, Yarui Ma, Junbo Liang, Zhewen Wei, Mo Li, Ying Zhang, Mei Liu, Huan He, Chunfeng Qu, Jianqiang Cai, Xiaobing Wang, Yixin Zeng, Yuchen Jiao

Affiliations

  1. State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  2. State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China.
  3. Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  4. State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [email protected].
  5. Key Laboratory of Gene Editing Screening and R&D of Digestive System Tumor Drugs, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. [email protected].
  6. State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [email protected].
  7. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. [email protected].
  8. State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [email protected].
  9. Key Laboratory of Gene Editing Screening and R&D of Digestive System Tumor Drugs, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. [email protected].
  10. Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [email protected].

PMID: 34924560 PMCID: PMC8685275 DOI: 10.1038/s41392-021-00794-y

[No abstract available.]

References

  1. Signal Transduct Target Ther. 2021 Aug 9;6(1):299 - PubMed

Publication Types